$CBDY
Target Group Inc. Stock $cbdy

$cbdy Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000248 Filed on March 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.920M	$1.915M	$3.720M
YoY Change
Cost Of Revenue	$1.110M	$1.242M	$2.065M
YoY Change
Gross Profit	$810.2K	$673.3K	$1.655M
YoY Change
Gross Profit Margin	42.2%	35.16%	44.49%
Selling, General & Admin	$388.5K	$367.7K	$1.412M
YoY Change	185.12%	8.05%	11.78%
% of Gross Profit	47.95%	54.61%	85.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$236.0K	$131.6K	$811.6K
YoY Change	10.95%	-37.87%	-8.31%
% of Gross Profit	29.13%	19.55%	49.04%
Operating Expenses	$699.0K	$596.7K	$2.086M
YoY Change	105.16%	82.84%	68.32%
Operating Profit	$111.2K	$76.66K	-$431.3K
YoY Change			-65.21%
Interest Expense	$349.3K	-$397.3K	$1.411M
YoY Change	-1.21%	62.12%	25.8%
% of Operating Profit	314.27%	-518.29%
Other Income/Expense, Net	-$304.3K	-$7.870K	$107.6K
YoY Change	-24.86%	-112.23%	-103.28%
Pretax Income	-$193.2K	-$185.0K	-$323.7K
YoY Change	-74.1%	-95.28%	-92.84%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$193.2K	-$185.0K	-$323.7K
YoY Change	-74.1%	-95.28%	-92.84%
Net Earnings / Revenue	-10.06%	-9.66%	-8.7%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	617.0M	617.0M	617.0M
Diluted Shares Outstanding	617.0M		617.0M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$745.6K	$736.3K	$736.3K
YoY Change	1411.11%	228.95%	228.95%
Cash & Equivalents	$754.1K	$745.0K
Short-Term Investments
Other Short-Term Assets	$50.19K	$55.27K	$106.7K
YoY Change	-92.68%	-91.88%	-84.32%
Inventory	$738.1K	$1.216M	$1.216M
Prepaid Expenses	$41.70K	$42.72K
Receivables	$88.70K	$1.032M	$1.032M
Other Receivables	$70.70K	$3.780K	$3.780K
Total Short-Term Assets	$1.693M	$3.094M	$3.094M
YoY Change	124.16%	240.03%	240.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.068M	$5.430M	$5.477M
YoY Change	-5.21%	-2.23%	-2.49%
Goodwill	$263.0K	$269.5K
YoY Change	-0.12%	2.41%
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets
YoY Change
Total Long-Term Assets	$5.377M	$5.747M	$5.747M
YoY Change	-22.5%	-13.66%	-13.66%
TOTAL ASSETS
Total Short-Term Assets	$1.693M	$3.094M	$3.094M
Total Long-Term Assets	$5.377M	$5.747M	$5.747M
Total Assets	$7.071M	$8.841M	$8.841M
YoY Change	-8.1%	16.86%	16.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$428.0K	$372.0K	$372.0K
YoY Change	-94.36%	-92.73%	-92.73%
Accrued Expenses	$2.067M	$2.750M	$2.750M
YoY Change	1730.05%	53.48%	53.48%
Deferred Revenue
YoY Change
Short-Term Debt	$990.00	$990.00	$990.00
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due	$7.692M	$7.880M	$11.42M
YoY Change	371.37%	353.69%	155.47%
Total Short-Term Liabilities	$12.98M	$14.59M	$14.59M
YoY Change	68.44%	110.6%	110.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$1.160M	$1.224M	$1.224M
YoY Change	-10.18%	-7.26%	-7.26%
Total Long-Term Liabilities	$1.160M	$1.224M	$1.224M
YoY Change	-84.09%	-82.99%	-82.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.98M	$14.59M	$14.59M
Total Long-Term Liabilities	$1.160M	$1.224M	$1.224M
Total Liabilities	$14.14M	$15.81M	$15.81M
YoY Change	-5.72%	11.95%	11.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.30M	-$31.11M
YoY Change	-0.73%	1.05%
Common Stock	$61.70K	$61.70K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.073M	-$6.973M	-$6.973M
YoY Change
Total Liabilities & Shareholders Equity	$7.071M	$8.841M	$8.841M
YoY Change	-8.1%	16.86%	16.86%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$193.2K	-$185.0K	-$323.7K
YoY Change	-74.1%	-95.28%	-92.84%
Depreciation, Depletion And Amortization	$236.0K	$131.6K	$811.6K
YoY Change	10.95%	-37.87%	-8.31%
Cash From Operating Activities	$774.4K	$290.4K	-$589.6K
YoY Change	-514.68%	424.36%	-41.9%
INVESTING ACTIVITIES
Capital Expenditures	$2.520K	$12.09K	$22.09K
YoY Change		-121000.0%	7025.81%
Acquisitions
YoY Change
Other Investing Activities		-$980.00	$439.0K
YoY Change		-99.56%	-56.76%
Cash From Investing Activities	-$2.517K	-$23.07K	$416.9K
YoY Change	-99.53%	-89.75%	-58.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-741.5K	-3.100K	666.9K
YoY Change	-233.71%	-101.61%	443.64%
NET CHANGE
Cash From Operating Activities	774.4K	290.4K	-589.6K
Cash From Investing Activities	-2.517K	-23.07K	416.9K
Cash From Financing Activities	-741.5K	-3.100K	666.9K
Net Change In Cash	30.43K	264.2K	494.2K
YoY Change	-117.78%	1029.63%	302.18%
FREE CASH FLOW
Cash From Operating Activities	$774.4K	$290.4K	-$589.6K
Capital Expenditures	$2.520K	$12.09K	$22.09K
Free Cash Flow	$771.9K	$278.3K	-$611.7K
YoY Change	-513.33%	402.44%	-39.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001586554
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Trading Symbol TradingSymbol	CBDY
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55066
CY2023	dei	Entity Registrant Name EntityRegistrantName	TARGET GROUP INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3621499
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 Hempstead DriveHamilton
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ontario
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	L8W 2E7
CY2023	dei	City Area Code CityAreaCode	+1 905
CY2023	dei	Local Phone Number LocalPhoneNumber	541-3833
CY2023	dei	Security12g Title Security12gTitle	Common Stock, Par Value $0.0001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8021
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15125
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14589289
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4627695
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	617025999
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q4	us-gaap	Cash Cash	736323
CY2022Q4	us-gaap	Cash Cash	223843
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	8696
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	8490
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1031530
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2068
CY2023Q4	us-gaap	Inventory Net InventoryNet	1215928
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	42720
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	41714
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55268
CY2022Q4	cbdy	Receivables From Joint Venture Current ReceivablesFromJointVentureCurrent	630180
CY2023Q4	us-gaap	Other Receivables OtherReceivables	3781
CY2022Q4	us-gaap	Other Receivables OtherReceivables	3692
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3094246
CY2022Q4	us-gaap	Assets Current AssetsCurrent	909987
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5430260
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5554225
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	775577
CY2023Q4	us-gaap	Goodwill Goodwill	269460
CY2022Q4	us-gaap	Goodwill Goodwill	263117
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46936
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62728
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5746656
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6655647
CY2023Q4	us-gaap	Assets Assets	8840902
CY2022Q4	us-gaap	Assets Assets	7565634
CY2023Q4	us-gaap	Bank Overdrafts BankOverdrafts	506
CY2022Q4	us-gaap	Bank Overdrafts BankOverdrafts	506
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2945568
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2296935
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	43098
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	48581
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	35254
CY2023Q4	cbdy	Related Party Payables Net Current RelatedPartyPayablesNetCurrent	11415557
CY2022Q4	cbdy	Related Party Payables Net Current RelatedPartyPayablesNetCurrent	4468535
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127478
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110586
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	480
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	480
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6927421
CY2022Q4	us-gaap	Accounts Payable Interest Bearing Noncurrent AccountsPayableInterestBearingNoncurrent	5877930
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1223955
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1319619
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	355
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	489
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1224310
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7198038
CY2023Q4	us-gaap	Liabilities Liabilities	15813599
CY2022Q4	us-gaap	Liabilities Liabilities	14125459
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	100
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	100
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	61703
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	61703
CY2023Q4	cbdy	Shares To Be Issued Total SharesToBeIssuedTotal	175439
CY2022Q4	cbdy	Shares To Be Issued Total SharesToBeIssuedTotal	175182
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24985697
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24985697
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31107348
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30783678
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1088288
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-998829
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6972697
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6559825
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8840902
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7565634
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3720169
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2065149
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
CY2023	us-gaap	Gross Profit GrossProfit	1655020
CY2022	us-gaap	Gross Profit GrossProfit	0
CY2023	us-gaap	Professional Fees ProfessionalFees	147787
CY2022	us-gaap	Professional Fees ProfessionalFees	18926
CY2023	us-gaap	Management Fee Expense ManagementFeeExpense	312969
CY2022	us-gaap	Management Fee Expense ManagementFeeExpense	143677
CY2023	us-gaap	Legal Fees LegalFees	212427
CY2022	us-gaap	Legal Fees LegalFees	243670
CY2023	us-gaap	Depreciation Depreciation	811649
CY2022	us-gaap	Depreciation Depreciation	885229
CY2023	cbdy	Operating Lease Income Expense OperatingLeaseIncomeExpense	-190185
CY2022	cbdy	Operating Lease Income Expense OperatingLeaseIncomeExpense	74059
CY2023	cbdy	General And Administrative Income Expense GeneralAndAdministrativeIncomeExpense	-410576
CY2022	cbdy	General And Administrative Income Expense GeneralAndAdministrativeIncomeExpense	-22071
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	706
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	0
CY2023	us-gaap	Operating Expenses OperatingExpenses	2086299
CY2022	us-gaap	Operating Expenses OperatingExpenses	1239514
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7238
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	14383
CY2023	cbdy	Gain Loss On Settlement Of Liability GainLossOnSettlementOfLiability	1571742
CY2022	cbdy	Gain Loss On Settlement Of Liability GainLossOnSettlementOfLiability	0
CY2023	us-gaap	Interest Expense InterestExpense	1410974
CY2022	us-gaap	Interest Expense InterestExpense	1121595
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-51811
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	126314
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	16782
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	811464
CY2022	cbdy	Allowance Recovery For Sales Tax Recoverable AllowanceRecoveryForSalesTaxRecoverable	496
CY2022	cbdy	Impairment Of Inventory ImpairmentOfInventory	99000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3315749
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	24152
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	354736
CY2023	cbdy	Debt Issuance Costs DebtIssuanceCosts	49520
CY2022	cbdy	Debt Issuance Costs DebtIssuanceCosts	51599
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	107609
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3280550
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-323670
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4520064
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-323670
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4520064
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89459
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	111891
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-413129
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4408173
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.0005
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.0005
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.0073
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.0073
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	617025999
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	617025999
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	617025999
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	617025999
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6559825
CY2023	cbdy	Shares To Be Issued As Compensation To Intellectual Property Rights Value SharesToBeIssuedAsCompensationToIntellectualPropertyRightsValue	257
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-323670
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89459
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6972697
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2152112
CY2022	cbdy	Shares To Be Issued As Compensation To Intellectual Property Rights Value SharesToBeIssuedAsCompensationToIntellectualPropertyRightsValue	460
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4520064
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	111891
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6559825
CY2023	us-gaap	Profit Loss ProfitLoss	-323670
CY2022	us-gaap	Profit Loss ProfitLoss	-4520064
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7238
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	14383
CY2023	cbdy	Gain Loss On Settlement Of Liability GainLossOnSettlementOfLiability	1571742
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	821
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1660
CY2022	cbdy	Allowance For Sales Tax Recoverable AllowanceForSalesTaxRecoverable	496
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	811649
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	885229
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	233859
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	258916
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	24152
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	354736
CY2023	cbdy	Debt Issuance Costs DebtIssuanceCosts	49520
CY2022	cbdy	Debt Issuance Costs DebtIssuanceCosts	51599
CY2022	cbdy	Impairment Of Inventory ImpairmentOfInventory	99000
CY2022	cbdy	Impairment Of Goodwill ImpairmentOfGoodwill	3315749
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1008903
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54164
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-588896
CY2023	cbdy	Increase Decrease In Sales Tax Recoverable IncreaseDecreaseInSalesTaxRecoverable	12227
CY2022	cbdy	Increase Decrease In Sales Tax Recoverable IncreaseDecreaseInSalesTaxRecoverable	58310
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	981699
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-466139
CY2023	cbdy	Change In Operating Lease Liability Net ChangeInOperatingLeaseLiabilityNet	320651
CY2022	cbdy	Change In Operating Lease Liability Net ChangeInOperatingLeaseLiabilityNet	329473
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	42237
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-589612
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1014828
CY2023	cbdy	Payments For Proceeds From Property Plant And Equipment PaymentsForProceedsFromPropertyPlantAndEquipment	22086
CY2022	cbdy	Payments For Proceeds From Property Plant And Equipment PaymentsForProceedsFromPropertyPlantAndEquipment	314
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-439018
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-1015354
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	416932
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1015040
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	666900
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	269150
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	136476
CY2022	cbdy	Payment For Settlement Payable PaymentForSettlementPayable	10000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	666900
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122674
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	494220
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	122886
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18466
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12704
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	232333
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122151
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	745019
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	232333
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	460
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	280
CY2023	us-gaap	Interest Paid Net InterestPaidNet	877193
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2132332
CY2023Q4	us-gaap	Area Of Land AreaOfLand	44000
CY2022	cbdy	Revenue From Investments In Joint Venture RevenueFromInvestmentsInJointVenture	3916539
CY2023Q4	cbdy	Working Capital Deficit WorkingCapitalDeficit	11495043
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31107348
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2023Q4	cbdy	Number Of Customers NumberOfCustomers	2
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3720169
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2023	cbdy	Revenue From Investments In Joint Venture RevenueFromInvestmentsInJointVenture	791285
CY2023	cbdy	Foreign Currency Translation ForeignCurrencyTranslation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. In addition, effective April 1, 2019, the Company changed its functional currency from United States Dollar to Canadian Dollar thereby having an impact on additional paid-in capital and accumulated comprehensive income (loss). The presentation currency of the Company has remained unchanged at United States Dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from the translation of these foreign currency transactions are included in net income (loss) for the year. In translating the consolidated financial statements of the Company and its Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in cumulative other comprehensive income (loss) in stockholders’ equity. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high-quality banking institutions. The Company has cash balances in excess of the Federal Deposit Insurance Corporation limit as of December 31, 2023 whereas cash balances were not in excess of FDIC limit as of December 31, 2022.</p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	54909
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	53813
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	1215928
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	784354
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	431574
CY2023Q4	us-gaap	Inventory Net InventoryNet	1215928
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	42720
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	41714
CY2023Q4	cbdy	Allowance On Value Added Tax Recoverable AllowanceOnValueAddedTaxRecoverable	0
CY2022Q4	cbdy	Allowance On Value Added Tax Recoverable AllowanceOnValueAddedTaxRecoverable	0
CY2023Q4	cbdy	Gross Investment In Joint Venture GrossInvestmentInJointVenture	1593068
CY2023	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture	776382
CY2023Q4	cbdy	Net Amount Of Investment In Joint Venture NetAmountOfInvestmentInJointVenture	816686
CY2017Q3	us-gaap	Area Of Land AreaOfLand	44000
CY2019Q2	us-gaap	Area Of Land AreaOfLand	44000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9154374
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3724114
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5430260
CY2023Q4	cbdy	Equity Method Investments Joint Venture EquityMethodInvestmentsJointVenture	1023608
CY2023Q4	cbdy	Receivables From Joint Venture ReceivablesFromJointVenture	698645
CY2023Q4	cbdy	Payable To Joint Venture PayableToJointVenture	-129185
CY2023	cbdy	Asset Acquired Fair Value Of Accounts Receivables Joint Venture AssetAcquiredFairValueOfAccountsReceivablesJointVenture	163244
CY2023	cbdy	Asset Acquired Fair Value Of Inventory Joint Venture AssetAcquiredFairValueOfInventoryJointVenture	1690368
CY2023	cbdy	Asset Acquired Fair Value Of Fixed Assets Joint Venture AssetAcquiredFairValueOfFixedAssetsJointVenture	534816
CY2023Q4	cbdy	Asset Acquired Fair Value Joint Venture AssetAcquiredFairValueJointVenture	2388428
CY2023	cbdy	Gain Loss Net On Consolidation Of Joint Venture GainLossNetOnConsolidationOfJointVenture	1571742
CY2023Q2	cbdy	Equity Method Investments Joint Venture EquityMethodInvestmentsJointVenture	1023608
CY2023Q2	cbdy	Receivables From Joint Venture ReceivablesFromJointVenture	706598
CY2023Q2	cbdy	Release And Settlement Amount To Come Out Of Joint Venture ReleaseAndSettlementAmountToComeOutOfJointVenture	776382
CY2023Q2	cbdy	Investment In Joint Venture Balance InvestmentInJointVentureBalance	953824
CY2023Q2	cbdy	Gain From Termination Of Joint Venture GainFromTerminationOfJointVenture	1571742
CY2023	cbdy	Class Of Warrant Or Right Warrants Exercised During Period ClassOfWarrantOrRightWarrantsExercisedDuringPeriod	0
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2945568
CY2023Q4	cbdy	Accrued Consulting And Construction Services AccruedConsultingAndConstructionServices	126059
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1628007
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	945615
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2296935
CY2022Q4	cbdy	Accrued Consulting And Construction Services AccruedConsultingAndConstructionServices	154811
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	739130
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	906596
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3446680
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4433794
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	7880474
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	7880474
CY2020Q3	cbdy	Debt Issuance Costs DebtIssuanceCosts	251518
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	82159
CY2023Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	50733
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	31426
CY2023Q4	cbdy	Accrued Interest Converted Into Principal AccruedInterestConvertedIntoPrincipal	665640
CY2023Q4	cbdy	Accrued Interest Converted Into Principal AccruedInterestConvertedIntoPrincipal	900000
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	3886380
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	2938492
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	3786380
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	2862882
CY2023	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	991091
CY2023	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	1337504
CY2023Q4	cbdy	Line Of Credit Facility Accrued Interest LineOfCreditFacilityAccruedInterest	996565
CY2023Q4	cbdy	Line Of Credit Facility Accrued Interest LineOfCreditFacilityAccruedInterest	1265164
CY2023	cbdy	Number Of Operating Lease Facilities NumberOfOperatingLeaseFacilities	2
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.16
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M29D
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	330456
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	333761
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	337098
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	340469
CY2023Q4	cbdy	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	808116
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2149900
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	798467
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1351433
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127478
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1223955
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.250
CY2023	cbdy	Gross Operating Lease Expense GrossOperatingLeaseExpense	233859
CY2022	cbdy	Gross Operating Lease Expense GrossOperatingLeaseExpense	258916
CY2023	cbdy	Gross Operating Leases Rent And Utilities Expenses GrossOperatingLeasesRentAndUtilitiesExpenses	241110
CY2022	cbdy	Gross Operating Leases Rent And Utilities Expenses GrossOperatingLeasesRentAndUtilitiesExpenses	594498
CY2023	cbdy	Recoverable Expenses From Jv Co Related To Rent And Utilities RecoverableExpensesFromJvCoRelatedToRentAndUtilities	284784
CY2022	cbdy	Recoverable Expenses From Jv Co Related To Rent And Utilities RecoverableExpensesFromJvCoRelatedToRentAndUtilities	927473
CY2023	cbdy	Operating Lease Expenses Total OperatingLeaseExpensesTotal	190185
CY2022	cbdy	Operating Lease Expenses Total OperatingLeaseExpensesTotal	-74059
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	39
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	37
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15125
CY2023	cbdy	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-7104
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8021
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	850000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	850000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	617025999
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	617025999
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	100
CY2023	cbdy	Schedule Of Shares To Be Issued ScheduleOfSharesToBeIssued	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;width:51.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:51.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">80,000 shares of common stock to be issued as compensation to advisers and consultants. These were recorded at fair value of $52,000, based on the market price of the Company’s stock on the date of issue. 35,000 to be issued as settlement of the amount due for website development services amounting to $247,306. The fair value of the shares on the date of settlement was $21,000, resulting in a gain on settlement amounting to $226,306 during the year ended December 31, 2017.</p></td></tr><tr><td style="vertical-align:bottom;width:27.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Private placements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:51.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration for private placements with the fair value based on cash proceeds received. Proper allocation between common stock and additional paid-in capital of the amount received will be completed in the period when the shares are issued.</p></td></tr><tr><td style="vertical-align:bottom;width:27.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of loans of CannaKorp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 930,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:51.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Refer to Note 15 for details.</p></td></tr><tr><td style="vertical-align:bottom;width:27.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agreement with Serious Seeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 249,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:51.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As consideration for intellectual property rights granted by Smit. The fair value is based on the market price of the Company’s stock on the date of issue as per the agreement.</p></td></tr><tr><td style="vertical-align:bottom;width:27.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,641,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	115000
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	73000
CY2023Q4	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2023Q3	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2023Q2	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2023Q1	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.350
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.300
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.300
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	4.38
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.99
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.42
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.05
CY2023Q4	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2023Q3	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2023Q2	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2023Q1	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	158
CY2023Q3	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	313
CY2023Q2	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	138
CY2023Q1	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	160
CY2022Q4	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2022Q3	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2022Q2	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2022Q1	cbdy	Share Based Compensation Share Based Payments Forfeiture Rate ShareBasedCompensationShareBasedPaymentsForfeitureRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.300
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.300
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.300
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.79
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.79
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.99
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.06
CY2022Q4	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2022Q3	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2022Q2	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2022Q1	cbdy	Fair Value Assumptions Term FairValueAssumptionsTerm	P2Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	176
CY2022Q3	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	288
CY2022Q2	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	306
CY2022Q1	cbdy	Business Acquisition Fair Value Of Equity Interest Issued Or Issuable BusinessAcquisitionFairValueOfEquityInterestIssuedOrIssuable	430
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10400008
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	53950001
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	350178339
CY2022	cbdy	Number Of Warrants Issued During Period NumberOfWarrantsIssuedDuringPeriod	200004
CY2022	cbdy	Number Of Warrant Expired During Period NumberOfWarrantExpiredDuringPeriod	296428342
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	53950001
CY2023	cbdy	Number Of Warrants Issued During Period NumberOfWarrantsIssuedDuringPeriod	200004
CY2023	cbdy	Number Of Warrant Expired During Period NumberOfWarrantExpiredDuringPeriod	43749997
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10400008
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22095
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1221
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-22827
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	489
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	769
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-903
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	355
CY2023	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1408467
CY2023	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1862805
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10720
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	cbdy	Net Income Loss After Adjustment Of New Tax Law NetIncomeLossAfterAdjustmentOfNewTaxLaw	-67971
CY2022	cbdy	Net Income Loss After Adjustment Of New Tax Law NetIncomeLossAfterAdjustmentOfNewTaxLaw	-949213
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	331532
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3099
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-399503
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-952312
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5419579
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5020076
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5419579
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5020076
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25807517
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23905124
CY2023	cbdy	Operating Loss Expiration Period Description OperatingLossExpirationPeriodDescription	2042
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001410578-24-000248-index-headers.html	Edgar Link	pending
0001410578-24-000248-index.html	Edgar Link	pending
0001410578-24-000248.txt	Edgar Link	pending
0001410578-24-000248-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20231231.xsd	Edgar Link	pending
tmb-20231231x10k.htm	Edgar Link	pending
tmb-20231231x10k001.jpg	Edgar Link	pending
tmb-20231231x10k002.jpg	Edgar Link	pending
tmb-20231231xex31d1.htm	Edgar Link	pending
tmb-20231231xex32d1.htm	Edgar Link	pending
tmb-20231231_def.xml	Edgar Link	unprocessable
tmb-20231231_lab.xml	Edgar Link	unprocessable
tmb-20231231_pre.xml	Edgar Link	unprocessable
tmb-20231231x10k_htm.xml	Edgar Link	completed
tmb-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CBDY
Target Group Inc. Stock $cbdy

2024 Q1 Form 10-K Financial Statement

#000141057824000248 Filed on March 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBDY Target Group Inc. Stock $cbdy

2024 Q1 Form 10-K Financial Statement

#000141057824000248 Filed on March 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBDY
Target Group Inc. Stock $cbdy